Kornimate/medical-research-clean huggingface dataset:
impact of topical clobetasol on gingival crevicular fluid mirnas in subjects affected by oral lichen planus

Conditions: Oral Lichen Planus

Summary: according to recent research, micrornas (mirnas) may function as early disease indicators and contribute to the severity of a number of precancerous and malignant oral disorders. the aim of the present study, through a double-blind randomized controlled trial design, is to analyze in the gingival crevicular fluid (gcf) as a non-invasive approach the impact of topical clobetasol on mirnas expression in subjects affected by oral lichen planus (olp).

a double-blind randomized controlled clinical trial is conducted in order to evaluate the impact of topical clobetasol on gcf mirnas expression in subjects with olp and determine the statistical significance of the outcome variables. at least 60 patients with olp, randomly allocated in two groups: placebo group with a 4% hydroxyethyl cellulose adhesive gel and the clobetasol group with the same gel containing clobetasol propionate 0,05%.

Eligibility criteria:
inclusion criteria: * the complete correspondence of the most recent who clinical and histopathological criteria (2020) for olp diagnosis. exclusion criteria: * 1) previous therapies for olp during the last six months preceding the study; 2) state of pregnancy or breastfeeding; 3) contact or drug oral lichenoid lesions; 4) allergies to the molecules used in the study; 5) hiv seropositivity.
health effects of silver-mercury dental fillings

Conditions: Caries, Dental

Summary: the purpose of this study is to determine whether there are detectable health effects of low-level mercury exposure (from normal exposure to mercury-containing dental fillings) in the known target organs/systems affected by elemental mercury exposure.

the casa pia study of the health effects of dental amalgam in children is a randomized, prospective clinical trial with the overall goal of determining if there are detectable health effects due to exposure from mercury-containing dental amalgam fillings. children, thought to be the population most susceptible to any possible health effects, were randomly assigned to one of two treatment groups (total n=507). subjects were originally enrolled at ages between 8-10 years of age. to participate, subjects must have: dental caries in at least one posterior tooth; no prior exposure to dental amalgam; a blood lead of \ 67; and no prior or existing serious medical or neurologic condition. one group received only dental filling materials other than those containing mercury (plastic and ceramic composites), while the other group received mercury amalgam fillings where appropriate (in large restorations in back teeth), but the alternative materials everywhere else. both treatment regimens are standard-of-care throughout the world. subjects receive ongoing dental care via the study clinics, and continue to receive dental fillings as needed based on group assignment. the target organs of mercury exposure are renal and neurological. baseline and annual repeated measures are taken on all subjects for renal function, nerve conduction velocity and a large battery of neurobehavioral tests. follow-up is planned for a period of 7 years

Eligibility criteria:
* age 8-10 years of age * dental caries in at least one posterior tooth. * no prior exposure to dental amalgam * blood lead of \<15ug/l * urinary mercury level of \<10ug/l * iq as measured by the ctoni of \>67 * no prior or existing serious medical or neurologic condition

Keywords: neurologic nerve conduction neurobehavioral renal disease
feasibility and acceptability of a single session of imagery rescripting in a community sample of adults

Conditions: Feasibility Studies; Acceptability; Depressive Symptoms; Disordered Eating Behaviors

Summary: negative experiences related to eating and appearance (nereas), such as critical commentary from parents about food, are common. they are also associated with depression and disordered eating, predictors of early mortality. imagery rescripting (ir) is a therapeutic process during which individuals are guided through recalling distressing memories, like nereas, and generating ideas for bringing support into these memories. single sessions of ir demonstrate promise in shifting the primary negative consequences of nereas in clinical samples of women. the current study examined the feasibility and acceptability of a remote-delivered, single session of ir in a community sample of men and women with nereas.


Eligibility criteria:
inclusion criteria: 1. ≥18 years old 2. endorse a history of at least one negative experience related to eating and/or appearance exclusion criteria: 1. endorsed a current major medical condition; 2. met criteria for a full threshold psychiatric disorder (of moderate intensity when severity ratings are necessary, such as for substance use disorders and binge eating disorder); 3. were at high risk for suicide; 4. endorsed current or recent pregnancy or anticipated becoming pregnant within the next year; 5. were taking medication known to affect eating, weight and/or chronic disease risk; 6. were participating in eating, weight, or diabetes programming; 7. experienced weight loss \&gt; 10% in the past six months; and/or 8. could not complete study procedures in english.
study to investigate the seropersistence of tbe virus antibodies approx. 3 years after a booster vaccination with fsme-immun 0.25 ml junior in children

Conditions: Encephalitis, Tick-borne

Summary: the objective of this study is to assess the tbe antibody persistence approximately three years after administration of a tbe booster vaccination with fsme-immun 0.25 ml junior in children who received either 0.25 ml or 0.5 ml ticovac for their primary vaccination series in study 146a.


Eligibility criteria:
inclusion criteria: * male and female children who participated in study 146a if: * they and/or their parents/legal guardians understand the nature of the study and agree to its provisions * written informed consent is available from the child (according to age and capacity of understanding) and the parents/legal guardians * they received the complete 3-immunization primary vaccination series with either 0.5 ml or 0.25 ml ticovac in study 146a * they received fsme-immun 0.25 ml junior for their first booster vaccination approximately 3 to 4 years after their third vaccination in study imag-146a exclusion criteria: * subjects who received any further tbe vaccination since their first tbe booster vaccination * subjects with a history of infection with, or vaccination against, other flaviviruses (e.g. dengue fever, yellow fever and/or japanese b encephalitis virus) since their third vaccination in study 146a * subjects who have suffered from a disease (e.g. autoimmune disease) or have undergone a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions within 30 days before and after their first tbe booster vaccination * subjects who have been known to be hiv positive (a special hiv test is not required for the purpose of the study) since their third vaccination in study 146a * subjects who have received a blood transfusion or immunoglobulins within 30 days of study entry

Keywords: tick-borne encephalitis
far infrared radiation treatment for uterine fibroids

Conditions: Leiomyoma

Summary: a preliminary study to determine the efficacy of using energy specific far infrared (fir) radiation for the treatment of uterine fibroids.

uterine fibroids are the most common neoplasms of the female pelvis. these benign tumors are generally oval in shape and often highly vascular. on mr imaging exams, uterine fibroids are easily identifiable. they occur in 20-25% of women of reproductive age and can cause a variety of problems generally described as either bleeding or mass effects from the fibroid. we are postulating that energy specific electromagnetic radiation of the uterus will shrink the benign tumors.

Eligibility criteria:
inclusion criteria: * women age 18 or older with symptomatic fibroids exclusion criteria: * women who are pregnant, as confirmed by serum test at time of screening, or urine pregnancy test on the day of treatment * metallic implants that are incompatible with mri or ultrasound * known intolerance to the mri contrast agent (e.g. gadolinium)

Keywords: fibroid tumor fibroid uterus fibroids, uterine fibromyoma uterine neoplasms
monitoring response to neoadjuvant chemotherapy in breast cancer using ultrafast dce-mri

Conditions: Breast Cancer

Summary: the study will assess whether changes in kinetic parameters of tumor and peritumoral vasculature using ultrafast dynamic contrast enhanced magnetic resonance imaging (dce-mri) during neoadjuvant chemotherapy (nac) are predictive of pathologic complete response (pcr) in patients with breast cancer appropriate for nac. pcr is defined as having no residual invasive breast cancer or ductal carcinoma in situ.


Eligibility criteria:
inclusion criteria: 1. female; 2. age 18 years or older; 3. diagnosis of invasive breast cancer by ultrasound guided biopsy; 3. planed for receiving neoadjuvant chemotherapy (nac) 4. planned definitive breast surgery following completion of nac. exclusion criteria: 1. stage iv breast cancer; 2. previous ipsilateral breast cancer; 3. previous treatment (chemotherapy or radiation) to involved breast; 4. medically unstable; 5. pregnant or nursing.
clinical and radiographic evaluation of mineral trioxide aggregate and biodentine as pulp medicaments in primary molars

Conditions: Pulp Disease, Dental

Summary: the aim of the present study is to evaluate mineral trioxide aggregate and biodentine in direct pulp capping, partial pulpotomy, and pulpotomy in primary molars.

screening of patients will continue until the target population is achieved. identifying and recruiting potential subjects is achieved through patient database in pediatric dentistry department. a total of 150 primary molars from healthy subjects will be selected from the pediatric dentistry and dental public health outpatient clinic, faculty of dentistry, ain shams university. subjects will be assigned randomly into two different treatment groups as follows: mta group (1): 1. group 1(a): mta direct pulp capping. (n=25) 2. group 1 (b): mta partial pulpotomy. (n=25) 3. group 1 (c): mta complete pulpotomy. (n=25) biodentinetm group (2): 1. group 2(a): biodentinetm direct pulp capping. (n=25) 2. group 2 (b): biodentinetm partial pulpotomy. (n=25) 3. group 2 (c): biodentinetm complete pulpotomy. (n=25)

Eligibility criteria:
inclusion criteria: * no clinical symptoms or history implying irreversible pulpitis such as spontaneous pain, or pain persisting after stimuli removal. * absence of periapical or interadicular radiolucencies, inflammatory root resorption, sinus tract or gingival abscess. exclusion criteria: * children who are extremely uncooperative and difficult to manage. * children suffering from any physically or mentally disability that will complicate the treatment: special health care needs (shcn). * teeth of poor prognosis due to presence of an abscess or a sinus, mobility, advanced bone or root resorption or non-restorable teeth.

Keywords: direct pulp capping, partial pulpotomy, and pulpotomy
high-intensity vs low-intensity nppv in patients with an aecopd: the happen trial

Conditions: Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Summary: to determine whether high-intensity nppv, compared with low-intensity nppv, could reduce the need for endotracheal intubation during hospitalization in patients with an aecopd and hypercapnia.


Eligibility criteria:
inclusion criteria: * aecopd confirmed by the 2019 criteria of the global initiative for chronic obstructive lung disease (gold) * arterial ph \ 45 mmhg at screening entry * paco2 \>45 mmhg after a 6-hour trial of low-intensity nppv exclusion criteria: * age \<18 years * excessive respiratory secretions with weak cough * upper airway obstruction * recent oral, facial, or cranial trauma or surgery * recent gastric or esophageal surgery * presence of restrictive ventilatory dysfunction (eg, consolidation or removal of at least one pulmonary lobe, massive pleural effusion, chest wall deformity, continuous strapping with thoracic or abdominal bandage, or severe abdominal distension) * active upper gastrointestinal bleeding * cardiac or respiratory arrest * arterial oxygen tension/fraction of inspired oxygen (pao2/fio2) \<100 mmhg * pneumothorax * obvious emphysematous bullae confirmed by chest ct scan * ventricular arrhythmia or myocardial ischemia * severe hemodynamic instability (mean arterial pressure \<65 mmhg) * severe metabolic acidosis (ph \<7.20 and bicarbonate \<22 mmol/l) * refusal to receive nppv or give informed consent * prior endotracheal intubation or tracheostomy during the current hospitalization * a do-not-intubate order
intravitreal triamcinolone acetonide for diabetic macular edema

Conditions: Diabetic Retinopathy; Diabetic Macular Edema

Summary: efficacy duration of triamcinolone acetonide (steroid) for treatment of diabetic macular edema. furthermore, dosage dependency of triamcinolone acetonide comparing a high dosage versus a low dosage.

patients with diabetic retinopathy suffer from visual acuity loss caused by diabetic macular edema. intravitreal injected triamcinolone acetonide (steroid) reduces macular edema and increases visual acuity. the duration of its effect is however limited. therefore, several injections are necessary. in this study a dosage dependency of triamcinolone acetonide (high dosage vs low dosage) is performed. the primary outcome parameters are the number of treatments and the efficacy of each injection.

Eligibility criteria:
inclusion criteria: * diabetic macular edema and visual acuity between 20/200 and 20/40 age over 18 years exclusion criteria: * recent treatment with laser photocoagulation or intravitreal drugs

Keywords: diabetic macular edema triamcinolone acetonide intravitreal steroid
combination weekly taxotere™ with iressa™ /placebo in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: the purpose of this study is to determine if combination therapy of weekly taxotere™ with iressa™ will increase the objective responses in measurable leasions in metastatic breast cancer


Eligibility criteria:
inclusion criteria: * histologically confirmed mammary carcinoma exclusion criteria: * prior taxane chemotherapy for metastatic disease or prior treatment with tyrosine kinase inhibitors inhibiting the egf receptor. * prior hormone treatment or one type of anthracycline based treatment regimen without taxane for metastatic disease is allowed prior to inclusion. * if the patient has been treated in the adjuvant or neoadjuvant setting with taxanes, inclusion is allowed when the first cycle of trial medication is started 12 months after the last course of adjuvant treatment
comparison of different hes coload volumes on the 90% ed of norepinephrine

Conditions: Adverse Effect

Summary: the purpose of this study is to investigate the effect of different 6% hydroxyethyl starch (130/0.4) coload volumes on the 90% effective dose of norepinephrine infusion prophylaxis for hypotension during spinal anesthesia for cesarean section.

post-spinal anesthesia hypotension is a frequent complication during spinal anesthesia for cesarean section. the incidence of post-spinal anesthesia hypotension is as high as 62.1-89.7% if prophylactic measures are not taken. coload has been highly demonstrated for prevention and/or treatment of post-spinal anesthesia hypotension. in addition, there's some evidence that prophylactic infusion of norepinephrine could effectively reduce the incidence of post-spinal anesthesia hypotension in parturients undergoing cesarean section. the purpose of this study is to investigate the effect of different 6% hydroxyethyl starch (130/0.4) coload volumes on the 90% effective dose of norepinephrine infusion prophylaxis for hypotension during spinal anesthesia for cesarean section.

Eligibility criteria:
inclusion criteria: * 18-45 years * primipara or multipara * singleton pregnancy ≥37 weeks * american society of anesthesiologists physical status classification i to ii * scheduled for cesarean section under spinal anesthesia exclusion criteria: * body height \< 150 cm * body weight \> 100 kg or body mass index (bmi) ≥ 40 kg/m2 * eclampsia or chronic hypertension or baseline blood pressure ≥180 mmhg * hemoglobin \< 7g/dl * fetal distress, or known fetal developmental anomaly

Keywords: norepinephrine hydroxyethyl starch 130/0.4 postspinal anesthesia hypotension coload cesarean section
diagnostic, therapeutic and reproductive aspects of patients with mullerian anomalies

Conditions: Mullerian Anomaly of Uterus, Nec; Mullerian Anomaly of Vagina; Mullerian Anomaly of Cervix

Summary: the purpose of this study is to get a better understanding of the clinical implications (including reproductive problems and obstetric complications), appropriate diagnostic tools and correct surgical treatment of mullerian anomalies.

mullerian anomalies are rare, therefore they are not well known and not often considered as differential diagnosis. this causes a delay in the diagnosis with risk of long lasting symptoms and adverse effects on the reproductive function. however, the diagnosis can be made more accurately with improved diagnostic tools. moreover, minimally invasive surgery allows for preservation and potential improvement of fertility in these women. the purpose of this study is to get a better understanding of the clinical implications (including reproductive problems and obstetric complications), appropriate diagnostic tools and correct surgical treatment of mullerian anomalies.

Eligibility criteria:
inclusion criteria: * women with a uterus * presence of a mullerian variation * maximum age 45y exclusion criteria: * women without a uterus * aged \>45y

Keywords: mullerian anomaly diagnostic tools surgical treatment reproductive function obstetric complications
aromatherapy in management of postoperative nausea in post-bariatric surgery patients

Conditions: Bariatric Surgery Candidate; Nausea, Postoperative

Summary: determine the effectiveness of peppermint oil aromatherapy in relieving post-operative nausea in the bariatric surgery patient population.

healthy weight management and use of essential oils and aromatherapy as natural interventions to manage health-related issues are significantly growing interests. one frequent intervention for healthy weight management is bariatric surgery. in the post-operative period following bariatric surgery, nausea is a common consequence. peppermint oil aromatherapy is an effective intervention for relieving nausea and other gastrointestinal symptoms in the bariatric and surgical population. this study has multiple aims. one is to determine effectiveness of peppermint oil aromatherapy in relieving post-operative nausea in the bariatric surgery patient population. a second aim is to establish relative cost-effectiveness of peppermint oil aromatherapy versus traditional anti-emetic drug therapies. a third is to determine whether peppermint oil aromatherapy increases patient satisfaction versus anti-emetic drug therapies. this is a randomized study with control and experimental groups. the control group will receive no peppermint oil aromatherapy and only traditional anti-emetics as needed. the experimental group will receive peppermint oil aromatherapy and traditional anti-emetics as needed.

Eligibility criteria:
inclusion criteria: * bariatric surgery candidate on 7-lime at lancaster general hospital * scheduled for laparoscopic sleeve gastrectomy and laparoscopic roux-en-y (rny) procedures * between ages of 18 and 70 * surgical patient of either dr. james ku and dr. joseph mcphee exclusion criteria: * history of excessive sensitivity to peppermint oil, allergic response to peppermint oil and who state preference against aromatherapy * not alert and oriented or unable to follow directions will be excluded * severe reactive airway disease such as asthma or chronic obstructive pulmonary disease (copd) * possible exclusion for severe hypertension or atrial fibrillation
navigation services to avoid rehospitalization (navstar)

Conditions: Opioid-use Disorder; Cocaine Use Disorder; Alcohol Use Disorder

Summary: this study will examine the clinical effectiveness and health economic profile of services to link hospital patients with substance use disorders to addiction treatment, promote their medical stabilization, and reduce hospital re-admissions.

in recent years, the problem of rehospitalization has come under intense focus as a major contributor to preventable morbidity and escalating healthcare costs. substance use disorders are strongly associated with poor health outcomes and highly inefficient use of healthcare services, including repeat hospitalizations. interventions that increase adherence to recommendations for outpatient medical care and substance abuse treatment could potentially help recently-hospitalized individuals with substance use disorders to avoid unnecessary rehospitalization, associated morbidity, and medical expenses. the current study is a randomized controlled trial comparing the effectiveness of navigation services to avoid rehospitalization (navstar) vs. treatment-as-usual (tau) for hospital patients with co-occurring medical problems and substance use disorders. applying andersen's theoretical model of health service utilization, navstar will employ the promising strategies of patient navigation and motivational interventions to facilitate engagement in outpatient medical and substance abuse treatment, thereby lowering the likelihood of rehospitalization. patient navigators embedded within the substance abuse consultation liaison service at a large urban hospital will deliver patient-centered, proactive navigation and motivational services initiated during the hospital stay and continued for 3 months post-discharge. participants randomized to tau will receive usual care from the hospital and the substance abuse consultation liaison service, which includes referral to substance abuse treatment but no continued contact post-hospital discharge. participants will be assessed at study entry and again at 3-, 6-, and 12-months follow-up on various measures of healthcare utilization, substance use, and functioning. the primary outcome of interest is time-to-rehospitalization through 12 months. in addition, a range of secondary outcomes spanning the medical and substance abuse service areas will be assessed. the study will include an economic evaluation of the cost, incremental cost-effectiveness, and cost-benefits of navstar from the service provider perspective.

Eligibility criteria:
inclusion criteria: 1. adult (ages 18 and older) hospital patients; 2. current dsm-5 sud (not in remission) for alcohol, cocaine, or opioids 3. willing and able to provide informed consent. exclusion criteria: 1. current enrollment in sud treatment; 2. primary residence outside of baltimore city; 3. pregnant; 4. terminal medical condition (e.g., planned discharge to hospice); 5. hospitalized for a suicide attempt.